Novavax (NVAX, Financials) shares jumped 17.1% to $7.32 as of 1:10 p.m. ET on Wednesday after the company said it received a request from the U.S. Food and Drug Administration for additional postmarketing clinical data related to its COVID-19 vaccine license application.
The company said the FDA issued a formal information request tied to its Biologics License Application (BLA) and asked for a postmarketing commitment. Novavax said it aims to respond promptly to move the vaccine closer to full regulatory approval.
The request comes after the April 1 Prescription Drug User Fee Act deadline, during which Novavax said it had constructive discussions with the agency.
Novavax stated that while it believes its application is approvable, final approval remains contingent on meeting the FDA's requirements.
The company cautioned that its forward-looking statementsincluding its expectations for approvalare subject to risks and uncertainties.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.